Clinico-pathologic features of chronic myeloid leukemia and risk stratification according to sokal score

Journal of the College of Physicians and Surgeons Pakistan

Volumn 16, Issue 5, 2006, Pages 336-339

  Syed, Naveen Naz ^a   Usman, Mohammad ^a   Khaliq, Gulnaz ^b   Adil, Salman N ^a   Khurshid, Mohammad ^a  

^a AGA KHAN UNIVERSITY HOSPITAL   (Pakistan)

^b ABBASI SHAHEED HOSPITAL   (Pakistan)

Author keywords

Chronic myeloid leukemia; Philadelphia chromosome; Sokal score

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CHRONIC MYELOID LEUKEMIA; FEMALE; HUMAN; MALE; MIDDLE AGED; PATHOLOGY; RETROSPECTIVE STUDY;

ADOLESCENT; ADULT; AGED; CHILD; FEMALE; HUMANS; LEUKEMIA, MYELOID, CHRONIC; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 36048986005     PISSN: 1022386X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Goldman JM. Chronic myeloid leukemia. Curr Opin Hematol 1997; 4: 277-285
2. 2. Cortes J. Natural history and staging of chronic meyelogenous leukemia. Hematol Oncol Clin North Am 2004; 18: 569-584 (Pubitemid 38969132)
3. 3. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1031-1037 (Pubitemid 32267972)
4. Sinclair PB, Nacheva EP, Leversha M, Telford N, Chang J, Reid A, et al. Large deletion at the t(9;22) break point are common and may identify a poor prognosis subgroup of patients with chronic myeloid leukemia. Blood 2000; 95: 738-743
5. Cortes J, Kantarjian H. Advanced-phase chronic myeloid leukemia. Semin Hematol 2003; 40: 79-86.
6. Barnes DJ, MeIo JV. Management of chronic myeloid leukemia: target for molecular therapy. Semin Hematol 2003; 40: 34-49.
7. Goldman JM, Mughal TI. Chronic myeloid leukemia. In: Hoffbrand AV, Catovsky D, Tuddenham E, (edi). Postgraduate haematology. 5th ed. Oxford: Blackwell Publishing 2005; 603-618
8. Lichtman MA, Liesveld JL. Chronic myelogenous leukemia and related disorder. In: Beutler E, Coller BS, Lichtman M, Kipps TJ, Seligsohn U, (edi). William hematology. 6th ed. New York: McGrew Hill 2001.1085-1124
9. Cortes J, Kantarjian H, O'Brien S, Robertson LE, Pierce S, Talpaz M. Result of interferon-alpha therapy in patients with chronic myelogenous leukemia 60 years of age and older. Am J Med 1996; 100: 452-455
10. Reid AG, Huntly BJ, Grace C, Green AR, Nacheva EP. Survival implications of molecular heterogeneity in variant Philadelphiapositive chronic myeloid leukemia. Br J Haematol 2003; 121: 419-427
11. 11. Faderl S, Talpaz M, Estrov Z, Kantarjian HM. Chronic myeloid leukemia: biology and therapy. Ann Intern Med 1999; 131: 207-219 (Pubitemid 29365004)
12. 12. Cervantes F, Rozman C. A multivariate analysis of prognostic factors in chronic myeloid leukemia. Blood 1982; 60: 1298-1304 (Pubitemid 13211366)
13. Tura S, Baccarani M, Corbelli G. Staging of chronic myeloid leukemia. Br J Haematol 1981; 47: 105-119
14. Sokal JE, Cox EB, Baccarani M, Tura S, Gomez GA, Robertsm J, etal. Prognostic discrimination in "good-risk" chronic granulocytic leukemia. Blood 1984; 63: 789-799
15. Vardiman JW, Pierre R, Thiele J. Chronic myelogenous leukemia. In: Jaffe S, Harris NL, Stein H, Vardiman JW, (edi). Tumors of haematopoietic and lymphoid tissues. World Health Organization classification of tumours. Lyon: IARC 2001; 20-26
16. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA CancerJClin 2002; 52: 23-47.
17. Bhurgh Y, Bhurgri A, Hassan SH, Zaidi SH, Sankaranarayanan R, Parkin DM. Cancer incidence in Karachi: Pakistan: first results from Karachi Cancer Registry. Int J Cancer 2002; 85: 325-339
18. National clinical registry programme: consolidation report of cancer registries 1990-1996.
19. Deshmukh C, Saikia T, Bakshi A, Amare-Kadam P, Baisane C, Parikh P. Imatinib mesylate in chronic myeloid leukemia: a prospective, single arm, non-randomized study. J Assoc Physicians India 2005; 53: 291-295
20. Asif MJ, Chughtai N M, Iqbal Z, Ehsan A, Arif S. Pattern of chronic leukemia at Shaikh Zayed Hospital, Lahore. Proceeding Shaikh Zayed Postgrad Med Inst 2002; 16: 24-29
21. Hassan K, lkram N, Iqbal W, Latif MZ. Clinico-morphological features and prognostic indicators in chronic myeloid leukaemia. /RawalMed Coll 1998; 2: 11-14
22. Hussain N, Ayaz B, Nadia N, Ali Z. Pattern of female breast diseases in Karachi. Biomedica 2005; 21: 36-38
23. Berger U, Maywald O, Pfirrmann M, Lahaye T, Hochhaus A, Reiter A, et al. Gender aspects in chronic myeloid leukemia: long-term results of randomized studies, Leukemia 2005; 19: 984-989
24. Faderl S, Talpaz M, Estrov Z, O'Brien S, Kurzrock R, Kantarjian HM. The biology of chronic myeloid leukemia. N Engl J Med 1999; 341: 164-172
25. Savage DG, Szydlo RM, Goldman JM. Clinical features at diagnosis in 430 patients with chronic myeloid leukemia seen at a referral centre over a 16-year period. Br J Haematol 1997; 96: 111.